Drug resistant tuberculosis (TB) cases are primarily driven by transmission, however, treatment failure and acquisition of drug resistance are still significant issues in drug sensitive TB cases.
Abstract:
Drug resistant tuberculosis (TB) cases are primarily driven by transmission, however, treatment failure and acquisition of drug resistance are still significant issues in drug sensitive TB cases.
Study of gene expression in Mycobacterium tuberculosis (Mtb) isolated from poor outcome patients may offer clues towards prediction of treatment response. In the current study, expression of five non-drug target genes (ppsD, embC, Rv1457c, Rv1687c and recB) previously identified to be associated with drug resistance was studied in clinical isolates from patients with different treatment outcomes to examine its correlation to treatment response and acquisition of drug resistance in Mtb. Our results show that expression of ppsD, a gene involved in synthesis of cell wall lipid PDIM, was significantly increased in patients who developed drug resistance during treatment and patients who were drug resistant at diagnosis. On the other hand in longitudinal isolates collected during treatment, ppsD expression decreased consistently in patients who responded to treatment and became culture negative, while it increased in patients who did not respond to treatment as indicated by their culture positive status towards the end of treatment.
These results demonstrate that ppsD expression reflects treatment response in TB patients and hence can be potentially used as a marker for predicting treatment response. Additional longitudinal studies with a larger cohort of patients are required to establish application of ppsD expression as a marker of treatment response.
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Introduction:
India has the highest burden of tuberculosis (TB) with 2.8 million new cases reported in 2016 [1] .
According to India Annual TB report treatment outcome data for microbiologically confirmed cases in 2015 [2] , about 7% of new TB patients and 16% of retreatment TB patients either failed treatment or developed resistance or died despite treatment. In some states, the percentages are higher than the national average [2] . These patients represent the poor-responders of treatment, essentially the bacteria they harbor do not respond to treatment because of tolerance or resistance to anti-TB drugs. Although the percentage appears to be small, considering the number of estimated cases, it is substantially significant in terms of absolute numbers to be ignored.
Currently, methods to predict a priori patients that will respond to treatment or those who will develop drug resistance and respond poorly to treatment are lacking. Studying the bacterial physiology in poor outcome patients may offer clues towards prediction of treatment response.
Mycobacterium tuberculosis (Mtb) has developed several mechanisms to combat drug pressure.
The most stable mechanism is development of mutations in drug-specific target genes that make the drug ineffective [3] . Other alternate mechanisms like low cell wall permeability, modifying enzymes and efflux offers generalized protection against drug pressure [4, 5] . In addition, several studies have shown that these alternative mechanisms sequentially assist in the development of a stable drug resistance mechanism [4] . Studies targeting these mechanisms to improve the effectivity of existing treatments are available. Efflux inhibitors are shown to reduce the minimum inhibitory concentration (MIC) and increase susceptibility to drugs, thus showing promise as adjunct therapeuty [6] . Recent literature shows these mechanisms act in conjunction with drug resistant mutations to determine the ability of bacteria to respond to drugs [7] . Machado et.al. [7] showed that clinical strains with same mutation conferring antibiotic resistance had different MICs and this differences can be reduced by using efflux inhibitors. The contribution of these alternative drug resistance mechanisms to bacterial survival under drug pressure, therefore, cannot be overlooked making it pertinent to understand the role of these mechanisms.
Studying gene expression changes may indicate how these mechanisms relate to the development of drug resistance or response to treatment. Studies on global expression changes in longitudinal clinical isolates from patients who develop drug resistance during treatment and in drug resistant isolates from patients who were resistant at diagnosis have indicated potential candidate genes to predict drug resistance in clinical strains [8, 9] . The studies have also shown that deregulation of DNA repair mechanisms may have an influence on mutational abilities of the bacteria and hence enhance the bacterial ability to acquire specific drug target mutations. In an earlier publication, we systematically analyzed these changes using in vitro generated mono and multi-drug resistant strains and identified 5 critical genes that were not previously known to be associated with the development of drug resistance [10] . The 5 genes were ppsD and embC belonging to cell wall processes that determine cell permeability, recB belonging to DNA repair, Rv1457c and Rv1687c that are putative efflux proteins. In this study, we studied the expression of these five genes in clinical isolates from patients with different treatment outcomes to investigate its correlation to treatment response and acquisition of drug resistance in Mtb. Details of sample collection are described in Figure 1 . Sixty nine patients were lost to follow-up with reasons being-defaulter (18), expired (11), initial defaulter/shifted to private care (15) , referred out to a different health post(12), migrated (9) or others (4) . Of the 69 lost to FU patients who were alive, treatment outcome information at 6 months of treatment could be traced for 4 patients.
Materials and Methods:
Study Population and Sample collection
By design, patients detected as DR at baseline were not followed up, however, we received random follow-up samples (4 th , 6 th and 18 th month) of one patient from DMC, which were used for gene expression analysis. 
Sample Processing and Drug susceptibility testing
Quantitative-Real Time Polymerase Chain Reaction (qRTPCR) :
RNA extraction, cDNA preparation and qRTPCR were carried out as described earlier [10] .
Primers for ppsD, embC, Rv1457c, Rv1687c and recB were same as described in the earlier study [10] . Each sample was tested in duplicate and the experiment was repeated three times from multiple cDNA preparations. The fold change was calculated with respect to standard laboratory strain H37Rv using Ct method and fgd1 as the house-keeping gene.
Statistical Analysis of qRTPCR data:
Each group of data was subjected to normality test by the Shapiro Wilk test. The statistical significance for the study was calculated using Mann Whitney test. A p-value of less than 0.05 was considered significant. Both Mann Whitney and Shapiro Wilk test were performed using IBM-SPSS version 19 statistical software.
Genotyping of clinical isolates:
Genotyping was carried out to establish if the patient samples had the same strain of Mtb at baseline and follow-up. MIRU-VNTR (Mycobacterial interspersed repeat units-variable tandem repeats) was used for establishing the identity. For samples that gave inconclusive results by MIRU-VNTR, whole genome sequencing (WGS) was used to establish identity. MIRU-VNTR was carried out for 12-loci as described by Supply et. al [11] with minor modifications. The PCR for 12 loci was carried out individually using 12 sets of primers and conditions described by Supply et. al. [11] The resultant PCR fragments were analyzed by 1% agarose gel electrophoresis and the size estimated using gel analyzer with at least three lanes of 1Kb ladder as a marker. The estimated fragment size was assigned MIRU-VNTR alleles using Table- 1 from Additional file 2 as described in Ali et. al [12] . The alleles were analyzed using MIRU-VNTR plus web-based platform for strain identity. The analysis was performed when data for all 12 loci were available. For whole genome sequencing, DNA was extracted from the preserved pellet as described in Chatterjee et al [13] . The sequencing was carried out by Genotypic Technologies Pvt Ltd, Bangalore on Illumina NextSeq 500 platform. The raw data in the form of FASTQ files were further used for strain identification using Mykrobe Predictor (v 0.4.2) [14] .
SDS Challenge Experiment:
The experiment was carried out to investigate correlation between cell permeability of clinical strains with differing expression levels of ppsD. The permeability was measured as growth obtained in presence of a detergent sodium dodecyl sulfate (SDS) in the growth medium as compared to absence of detergent. M.tb clinical strains were grown to early log phase and a 10fold dilution series with optical densities of 0.01 to 0.0001 at 580 nm was used. 5 μl of each dilution was spotted in triplicates onto 7H11 agar plates containing 10% oleic acid-albumin-dextrosecatalase with or without 0.01% SDS. The colonies were observed at 4 weeks after plating and the colony forming ability at different dilutions were compared in presence and absence of SDS.
Results:
Differential gene expression was studied for clinical isolates from patients with known treatment outcome information. The dropouts who could not be followed-up for outcome information were excluded. Of the 67 patients with known outcome information, 48 patients were cured (smear or culture negative at the end of treatment), 7 patients had completed treatment, 5 patients had delayed culture conversion but eventually cured (culture positive at first or second follow-up, but negative at the end of treatment) and 5 patients had poor outcome (treatment failure). Among the 5 poor outcome patients, 1 patient was culture positive, smear negative and drug sensitive at the end of treatment and had a relapse after four months which was cured; 4 patients acquired MDR during treatment as recorded by RNTCP. Two kinds of differential gene expression analysis were performed-First, patient samples were grouped based on treatment outcome/ resistance status and the differential gene expression analysis performed at baseline. Second, gene expression of culture positive follow-up samples that had identical strain as baseline was compared to the respective baseline expression and correlated to treatment response of the patient. We compared gene expression levels of ppsD, embC, recB, Rv1457c and Rv1687c at baseline across these four groups. We observed that only ppsD showed differential expression in response to treatment. As evident from Fig 2, the median values of ppsD increased with respect to poor treatment response, i.e From 5.7 in the cured group to 8.3 in slow responders to 13 in MDR convert group. However, the change was statistically significant only between cured and MDR converts. Interestingly, the differential expression between the cured group and the patients who had MDR at baseline was also significantly different, suggesting an association of ppsD with the development of drug resistance. All other genes studied (embC, recB, Rv1457c and Rv1687c) did not show any significant effect with respect to treatment or drug resistance status (Fig 2) . Only Rv1457c and Rv1687c, the efflux genes showed a trend similar to ppsD, between the groups, although not statistically significant. This suggests that alternate drug resistance mechanisms like cell permeability and efflux mechanism have an important role in patient's response to treatment.
ppsD expression reflects treatment response in culture positive follow-up samples:
To understand how gene expression varies with treatment, gene expression was tested in culture positive longitudinal isolates with same strain identity. The expression levels in the follow-up sample was compared to the baseline expression levels. We had three types of patients (Table   1A&B) (Table 1B) . The patient's final outcome was recorded as MDR treatment failure and the patient shifted to XDR treatment regimen.
As can be seen from Fig 3, in P1-5, ppsD expression was consistently down-regulated in followup samples compared to baseline in all patients (Fig -3) . However, in the other genes studied, the change in expression levels were not consistent. -In both P6 and P7 patient samples, the expression of ppsD, embC and Rv1457c appeared to decrease with treatment initially (Fig 3) . However, after a period of responding to treatment as seen by culture negative status (Table 1A- (Table 1A -6 th month follow-up of P6, Table 1B -18 th month followup of P7), the expression levels of these 3 genes increased. Nevertheless, only ppsD showed treatment specific changes in all types of patients suggesting expression levels of ppsD reflects the patient's response to treatment (Fig 3) .
Cell permeability and ppsD expression are not directly correlated:
Since PDIM is critical for virulence, architecture and cell permeability [15, 16] , we hypothesized that ppsD expression levels may correlate to the level of cell permeability and thus influence treatment response. To check this, cell permeability of representative isolates from cured, slow responders, MDR converts and MDR at baseline groups were determined by their ability to grow in presence of detergent SDS. As evident from Fig 4, baseline isolates from different groups showed varying levels of growth retardation in presence of SDS (indicating higher permeable cell wall and hence more susceptibility to treatment). No direct correlation was observed between ability to grow on SDS with ppsD expression levels or treatment response. These results indicate that alterations in cell permeability alone may not explain the association of ppsD expression with treatment response in patients.
Discussion:
In the current study, we demonstrated that expression of ppsD, the gene involved in the synthesis of cell wall lipid PDIM, was significantly increased in patients with unfavourable treatment response. The isolates from patients who developed resistance during treatment (MDR convert) had higher ppsD expression than slow responders (delayed culture converters). Likewise, slow responders had higher ppsD expression than responsive cured patients (Fig 2) . Even in isolates from patients who had MDR at baseline, the ppsD expression was significantly higher compared to cured patients. The higher expression of ppsD in MDR converts and baseline MDR group suggest that ppsD is associated with the development of drug resistance corroborating the observations from the earlier in vitro study [10] . In addition, the study shows that the ppsD expression levels correlate to treatment response in individual patients during treatment (Fig 3) .
The ppsD expression decreased in comparison to baseline values when culture positive isolates were collected prior to the period of culture negativity (responsiveness to treatment) in patients.
However, ppsD expression levels increased to levels comparable to baseline in isolates of patients who showed a period of non-responsiveness (culture positivity) subsequent to a period of responsiveness to treatment (culture negativity) as seen in patients P6 and P7. This was observed irrespective of the resistance status of the isolates (P6 being DS and P7 being MDR). These results indicate that ppsD is involved in the development of drug resistance and response to treatment.
Interestingly, higher expression of ppsD at baseline in patients with unfavourable outcome suggest that ppsD expression levels can potentially be used as a marker for predicting response to treatment in TB patients undergoing treatment irrespective of the drug resistance status.
ppsD gene is one of the five genes involved in the synthesis of PDIM, a long-chain -diol (phthiocerol) esterified with two branched-chain mycocerosic acids located in the outer mycobacterial cell wall that has been implicated in Mtb virulence [17] . PDIM has also been implicated in determining cell wall permeability in Mtb [16] . In our earlier study [10] it was suggested that differential expression of ppsD probably affected the levels of PDIM and hence the integrity of cell wall indicating propensity of strains with high ppsD expression to resist entry of drugs and allowing development of resistance through other mechanisms. Corroborating it, the DNA repair mechanisms and efflux pathways were are also observed to be deregulated. However in the current study, in patient isolates, although we observed expression levels of efflux genes following a pattern similar to ppsD expression at baseline (Fig 2 Rv1687c panel) , the expression difference was not significant between the groups (cured, slow responders, MDR convert or MDR at baseline). In addition, the expression of efflux genes in longitudinal isolates did not show a "treatment response based" pattern similar to ppsD. Furthermore, SDS challenge experiments that determine cell permeability showed that there is no direct correlation between cell permeability and ppsD expression or treatment response. These results suggest that although the role of other mechanisms in treatment response and resistance development cannot be ruled out, ppsD may affect the treatment response of the Mtb to drugs through additional mechanisms. Studies have shown that strains that harbor mutation in ppsD leading to loss of PDIM synthesis are susceptible to interferon gamma (IFN-) mediated immunity [18] . It is possible that higher ppsD expression and hence higher levels of PDIM in strains resist IFN- mediated immunity in patients during treatment. Hence, a combination of both decreased permeability and increased resistance to the immune response of host may explain the differential treatment response in TB patients' harbouring strains with differential ppsD expression.
To the best of our knowledge, this is the first study that demonstrates an association between differential gene expression and response to treatment in TB patients. Several studies have identified mutations in non-drug target genes that may serve as a compensatory mechanism for fitness of drug resistant strains [19, 20] . Such mutations have been correlated to the mechanism of drug resistance but not to treatment response. The clinical isolates in our study may harbor such mutations that may explain differences in ppsD expression at baseline. Preliminary analysis of whole genome sequence carried out with isolates from our study did not yield any potential mutation in the promoter region or predicted regulators for ppsD expression (data not shown).
However, the presence of indirect mutations that may control its expression could not be verified.
In addition, in the current study, we have shown that the expression of ppsD varies with respect to treatment even in absence of observable drug resistance. Our results suggest that Mtb's response to treatment is a complex phenomenon and may involve a combination of genetic changes and regulation of gene expression.
In conclusion, we have shown that ppsD expression varies with response to treatment in both DS and MDR patients and hence can potentially serve as a marker for predicting treatment response.
However, the study was limited by the number of patient samples from whom complete sample and information were available due to high percentage of patients lost to follow-up. Hence, further research is warranted to confirm these findings in a larger cohort of patients and investigate its application as a predictor of treatment response. Moreover, ppsD is only one of the 8 genes that control PDIM synthesis. Hence this study raises several questions regarding the role of other genes involved in PDIM synthesis, how they correlate to treatment response and the genetic factors that determine the variability. Table- 1B. 
